- Advertise
- Contact Us
- Contribute
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
- About Us
© 2023 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
American Thyroid Association
Thyroid Ablation in Operating Rooms Result in Fewer Side Effects Than Ambulatory Settings
October 08, 2021
An analysis of nearly 400 patients suggests undergoing thyroid radiofrequency ablation in ambulatory settings was associated with increased risk of intraoperative, postoperative, and perioperative side effects than those performed in operating room settings.
ATA Study Details Risk Factors, Comorbidities Associated with Severe Thyroid Eye Disease
October 07, 2021
An analysis of more than 650 thyroid eye disease patients is providing clinicians with insight into the most common comorbidities and risk factors associated with increased disease severity in patients with TED.
Teprotumumab Proves Benefit in Longer Duration Thyroid Eye Disease
October 06, 2021
An analysis of data from OPTIC and OPTIC-X provide insight into the effects of teprotumumab in longer duration thyroid eye disease and among patients who were nonresponders in the original trial.
Proton Pump Inhibitors Do Not Interfere with Absorption of Tirosint-SOL
October 05, 2021
Results of a bioavailability, crossover study suggest use of proton pump inhibitors did not interfere with the absorption of levothyroxine sodium oral solution.